149 related articles for article (PubMed ID: 37602700)
1. Development of a
Lee JP; Corless BC; Gardner TJ; Scheinberg DA; Tan DS
Org Lett; 2023 Sep; 25(34):6295-6299. PubMed ID: 37602700
[TBL] [Abstract][Full Text] [Related]
2. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
3. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
4. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
5. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
Aldughaim MS; Alsaffar F; Barker MD
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
[TBL] [Abstract][Full Text] [Related]
6. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
7. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
Khan TH; Eno-Amooquaye EA; Searle F; Browne PJ; Osborn HM; Burke PJ
J Med Chem; 1999 Mar; 42(6):951-6. PubMed ID: 10090777
[TBL] [Abstract][Full Text] [Related]
9. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
Marais R; Spooner RA; Light Y; Martin J; Springer CJ
Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
[TBL] [Abstract][Full Text] [Related]
10. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
Capucha V; Mendes E; Francisco AP; Perry MJ
Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
[TBL] [Abstract][Full Text] [Related]
11. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
12. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.
Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK
Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309
[No Abstract] [Full Text] [Related]
13. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
14. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
[TBL] [Abstract][Full Text] [Related]
15. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
Springer CJ; Niculescu-Duvaz I; Pedley RB
J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive detection of carboxypeptidase G2 activity in vivo.
Jamin Y; Smyth L; Robinson SP; Poon ES; Eykyn TR; Springer CJ; Leach MO; Payne GS
NMR Biomed; 2011 May; 24(4):343-50. PubMed ID: 20891022
[TBL] [Abstract][Full Text] [Related]
17. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
[TBL] [Abstract][Full Text] [Related]
18. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy.
Marais R; Spooner RA; Stribbling SM; Light Y; Martin J; Springer CJ
Nat Biotechnol; 1997 Dec; 15(13):1373-7. PubMed ID: 9415889
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
[TBL] [Abstract][Full Text] [Related]
20. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS
NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
